目的 探討五苓膠囊聯(lián)合培哚普利叔丁胺片治療高血壓的臨床療效。方法 選取2017年4月—2017年9月在宜賓市第二人民醫(yī)院進(jìn)行治療的高血壓病患者76例作為研究對(duì)象，采用計(jì)算機(jī)將患者隨機(jī)分為對(duì)照組和治療組，每組各38例。對(duì)照組口服培哚普利叔丁胺片，4 mg/次，1次/d。治療組在對(duì)照組基礎(chǔ)上口服五苓膠囊，3粒/次，3次/d。兩組患者均治療4周。觀察兩組的臨床療效，比較兩組的血壓變化情況、臨床癥狀評(píng)分和血清細(xì)胞因子水平。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為81.58%、97.37%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組收縮壓（SBP）、舒張壓（DBP）均明顯降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組血壓變化明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組頭痛、耳鳴、眩暈、心煩評(píng)分均顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組臨床癥狀評(píng)分明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血清轉(zhuǎn)化生長(zhǎng)因子-β₁（TGF-β₁）、可溶性細(xì)胞間黏度分子-1（sICAM-1）、可溶性凝集素樣氧化低密度脂蛋白受體1（sLOX-1）、白細(xì)胞介素-4（IL-4）水平均顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組血清細(xì)胞因子明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 五苓膠囊聯(lián)合培哚普利叔丁胺片治療高血壓具有較好的臨床療效，可改善臨床癥狀，降低TGF-β₁、sICAM-1、sLOX-1、IL-4水平，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Wuling Capsules combined with Perindopril tert-Butylamine Tablets in treatment of hypertension. Methods Patients (76 cases) with hypertension in the Second People's Hospital of Yibin from April 2017 to September 2017 were randomly divided into control and treatment groups, and each group had 38 cases. Patients in the control group were po administered with Perindopril tert-Butylamine Tablets, 4 mg/time, once daily. Patients in the treatment group were po administered with Wuling Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and blood pressure changes, clinical symptom scores, and serum cytokine levels in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.58% and 97.37%, respectively, and there was difference between two groups (P < 0.05). After treatment, SBP and DBP in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And blood pressure in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the scores of headache, tinnitus, vertigo, and annoying in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And clinical symptom scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P <0.05). After treatment, the levels of TGF-β₁, sICAM-1, sLOX-1, and IL-4 in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And serum cytokine levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P <0.05). Conclusion Wuling Capsules combined with Perindopril tert-Butylamine Tablets has clinical curative effect in treatment of hypertension, can improve clinical symptoms, decrease the levels of TGF-β₁, sICAM-1, sLOX-1, and IL-4, which has a certain clinical application value.